Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

291
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
291
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.5K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.5K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

6.9K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.9K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

96
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
96
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

64
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
64

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aristolochic Acid-Induced Nephrotoxicity: Molecular Mechanisms and Potential Protective Approaches.

International journal of molecular sciences·2020
Same author

Structural insights into immunoglobulin M.

Science (New York, N.Y.)·2020
Same author

Mutations of two FERONIA-like receptor genes enhance rice blast resistance without growth penalty.

Journal of experimental botany·2020
Same author

Receptor kinase FERONIA regulates flowering time in Arabidopsis.

BMC plant biology·2020
Same author

Dual-hybrid direct random phase approximation and second-order screened exchange with nonlocal van der Waals correlations for noncovalent interactions.

Journal of computational chemistry·2020
Same author

Genetic and functional analysis of two missense mutations in CD46 predispose to postpartum atypical hemolytic uremic syndrome.

Clinica chimica acta; international journal of clinical chemistry·2020

Related Experiment Video

Updated: Jul 17, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K

Bayesian hierarchical model for dose-finding trial incorporating historical data.

Linxi Han1, Qiqi Deng2, Zhangyi He3

  • 1School of Mathematics, University of Bristol, Bristol, UK.

Journal of Biopharmaceutical Statistics
|September 7, 2023
PubMed
Summary

This study introduces a new Bayesian method to improve dose-finding trials by incorporating historical data from multiple dose groups. This approach aims to reduce sample size while maintaining statistical power in drug development.

Keywords:
Bayesian hierarchical frameworkDose findingbetween-trial heterogeneityhistorical borrowing

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Related Experiment Videos

Last Updated: Jul 17, 2025

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Area of Science:

  • Biostatistics
  • Pharmacometrics
  • Clinical Trial Design

Background:

  • The Multiple Comparison Procedure and Modelling (MCPMod) is effective for dose-finding studies but struggles with incorporating historical data due to its frequentist nature.
  • Existing Bayesian MCPMod (BMCPMod) can incorporate historical placebo data, but not data from active dose groups.

Purpose of the Study:

  • To develop a Bayesian hierarchical framework for dose-finding studies that incorporates historical data from multiple dose groups (placebo and active).
  • To model prognostic and predictive between-trial heterogeneity, especially when trial effect sizes differ.
  • To reduce the required sample size in dose-finding trials while preserving statistical power.

Main Methods:

  • Developed a Bayesian hierarchical model to integrate historical data from various dose groups.
  • Accounted for relationships between dose group responses and between-trial heterogeneity (prognostic and predictive).
  • Applied the framework to optimize dose-finding study design for efficiency.

Main Results:

  • The proposed Bayesian framework successfully incorporates historical data from multiple dose groups.
  • The model effectively handles between-trial heterogeneity, accommodating different effect sizes.
  • Demonstrated potential for sample size reduction in dose-finding studies.

Conclusions:

  • The novel Bayesian approach enhances the MCPMod technique by leveraging historical data from multiple sources.
  • This method offers a flexible and powerful tool for designing more efficient dose-finding clinical trials.
  • Facilitates robust dose selection while minimizing patient numbers and resource allocation.